460 related articles for article (PubMed ID: 9820264)
41. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial.
Willetts KE; Clements MS; Champion S; Ehsman S; Eden JA
BJU Int; 2003 Aug; 92(3):267-70. PubMed ID: 12887481
[TBL] [Abstract][Full Text] [Related]
42. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
[TBL] [Abstract][Full Text] [Related]
43. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.
Wilde MI; Goa KL
Drugs; 1999 Apr; 57(4):557-81. PubMed ID: 10235693
[TBL] [Abstract][Full Text] [Related]
44. [Extract of Serenoa repens in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms].
Amdii RE; Al' Shukri AS
Urologiia; 2018 May; (2):114-120. PubMed ID: 29901305
[TBL] [Abstract][Full Text] [Related]
45. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms.
Gerber GS; Zagaja GP; Bales GT; Chodak GW; Contreras BA
Urology; 1998 Jun; 51(6):1003-7. PubMed ID: 9609640
[TBL] [Abstract][Full Text] [Related]
46. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
Marberger MJ
Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
[TBL] [Abstract][Full Text] [Related]
47. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia.
Lee J; Andriole G; Avins A; Crawford ED; Foster H; Kaplan S; Kreder K; Kusek J; McCullough A; McVary K; Meleth S; Naslund M; Nickel JC; Nyberg L; Roehrborn C; Dale Williams O; Barry M
Clin Trials; 2009 Dec; 6(6):628-36. PubMed ID: 20007408
[TBL] [Abstract][Full Text] [Related]
48. The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Gerber GS; Fitzpatrick JM
BJU Int; 2004 Aug; 94(3):338-44. PubMed ID: 15291864
[TBL] [Abstract][Full Text] [Related]
49. Effects of Serenoa repens Alcohol Extract on Benign Prostate Hyperplasia.
Saidi S; Stavridis S; Stankov O; Dohcev S; Panov S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Sep; 38(2):123-129. PubMed ID: 28991765
[TBL] [Abstract][Full Text] [Related]
50. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
[TBL] [Abstract][Full Text] [Related]
51. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
[TBL] [Abstract][Full Text] [Related]
52. Saw palmetto for the treatment of men with lower urinary tract symptoms.
Gerber GS
J Urol; 2000 May; 163(5):1408-12. PubMed ID: 10751846
[TBL] [Abstract][Full Text] [Related]
53.
Franco JVA; Trivisonno LF; Sgarbossa N; Alvez GA; Fieiras C; Escobar Liquitay CM; Jung JH
World J Mens Health; 2024 Jul; 42(3):518-530. PubMed ID: 38164033
[TBL] [Abstract][Full Text] [Related]
54. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
MacDonald R; Wilt TJ
Urology; 2005 Oct; 66(4):780-8. PubMed ID: 16230138
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
Nickel JC; Fradet Y; Boake RC; Pommerville PJ; Perreault JP; Afridi SK; Elhilali MM
CMAJ; 1996 Nov; 155(9):1251-9. PubMed ID: 8911291
[TBL] [Abstract][Full Text] [Related]
56. Effect of D-004, a lipid extract from the Cuban royal palm fruit, on atypical prostate hyperplasia induced by phenylephrine in rats.
Arruzazabala ML; Más R; Molina V; Noa M; Carbajal D; Mendoza N
Drugs R D; 2006; 7(4):233-41. PubMed ID: 16784248
[TBL] [Abstract][Full Text] [Related]
57. A phytosterol-enriched saw palmetto supercritical CO
Sudeep HV; Venkatakrishna K; Amrutharaj B; Anitha ; Shyamprasad K
BMC Complement Altern Med; 2019 Oct; 19(1):270. PubMed ID: 31623582
[TBL] [Abstract][Full Text] [Related]
58. The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens.
Giannakopoulos X; Baltogiannis D; Giannakis D; Tasos A; Sofikitis N; Charalabopoulos K; Evangelou A
Adv Ther; 2002; 19(6):285-96. PubMed ID: 12665049
[TBL] [Abstract][Full Text] [Related]
59. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia.
Grasso M; Montesano A; Buonaguidi A; Castelli M; Lania C; Rigatti P; Rocco F; Cesana BM; Borghi C
Arch Esp Urol; 1995; 48(1):97-103. PubMed ID: 7537488
[TBL] [Abstract][Full Text] [Related]
60. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
